China Tian Yuan Healthcare : CHANGE OF DIRECTORS, CHAIRMAN OF THE BOARD, MEMBER OF THE NOMINATION COMMITTEE AND AUTHORISED REPRESENTATIVE

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED

中國天元醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 557)

CHANGE OF DIRECTORS, CHAIRMAN OF THE BOARD,

MEMBER OF THE NOMINATION COMMITTEE

AND AUTHORISED REPRESENTATIVE

CHANGE OF DIRECTORS

Resignation of executive director

The board (the "Board") of directors (the "Directors") of China Tian Yuan Healthcare Group Limited (the "Company") announces that Mr. JIANG Yulin ("Mr. Jiang") has tendered his resignation as executive director of the Company in order to devote more time to his personal endeavours, accordingly, Mr. Jiang ceased to be the Chairman of the Board and the member of the Nomination Committee of the Company with effect from 16 March 2020.

Mr. Jiang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude and appreciation to Mr. Jiang for his efforts and invaluable contribution to the Company during his tenure of office for the past years.

Appointment of executive director

The Board is pleased to announce that Mr. WANG Huabing, has been appointed as executive director, Chairman of the Board and member of Nomination Committee of the Company with effect from 16 March 2020.

1

Set out below are the biographical details of Mr. WANG Huabing:

Mr. WANG Huabing ("Mr. Wang")

Mr. Wang, aged 51, obtained a bachelor's degree from Chongqing Jiaotong University, a Doctor of Management and a professor-level senior engineer of Applied Research Institute from Wuhan University of Technology. Mr. Wang served as a general manager of Shandong Hi-Speed Road

• Bridge Maintenance Co., Ltd (a subsidiary of Shandong Hi-Speed Road and Bridge Co., Ltd., Shenzhen Stock Exchange Stock Code: 000498) from years of 2003 to 2006. Mr. Wang served as a general manager at Shandong Hi-Speed Company Limited ("SDHSCL", Shanghai Stock Exchange Stock Code: 600350) from years of 2006 to 2013. Mr. Wang was promoted to and served as vice general manager at Shandong Hi-speed Group Co. Ltd. ("SDHSG" the controlling shareholder of SDHSCL) from 2013 to 2017 and further promoted to executive vice general manager of SDHSG since 2017. Mr. Wang has extensive experience in the management.

Mr. Wang (i) has not held any position in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) does not hold any other position with the Company or any of its subsidiaries; and (iii) has no relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, so far as the Directors are aware of, Mr. Wang is not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the SFO. Mr. Wang will enter into a service agreement with the Company as an executive director until the next following annual general meeting. Pursuant to the articles of association of the Company, Mr. Wang will be subject to re-election upon the expiry of his term of office. Mr. Wang will receive remuneration as an executive director of the Company to be determined by Remuneration Committee of the Board with reference to, among others, his duties and responsibilities with the Company, his experience and the prevailing market conditions.

Save as disclosed above, there is no other information relating to Mr. Wang which needs to be disclosed pursuant to any of the requirements of paragraphs (h) to (v) of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange. Further, there are no other matters which need to be brought to the attention of the shareholders of the Company. The Board would like to take this opportunity to extend its warm welcome to Mr. Wang on joining the Board.

2

CHANGE OF AUTHORISED REPRESENTATIVE

The Board also announces that:

Mr. Jiang ceased to act as an authorised representative of the Company for the purpose of Rule

3.05 of the Listing Rules (the "Authorised Representative of the Company") with effect from 16 March 2020; and Mr. Wang has been appointed as the Authorised Representative of the Company with effect from 16 March 2020.

By order of the board

China Tian Yuan Healthcare Group Limited

Zhang Xian

Executive Director

Hong Kong, 16 March 2020

As at the date of this announcement, the Board is composed of eight directors of which Mr. Wang Huabing (chairman) and Ms. Zhang Xian are the executive directors, Ms. He Mei, Mr. Zhang Yupeng and Mr. Zhou Yuan are the non-executive directors and Mr. Hu Baihe, Mr. Yuen Kwok Kuen and Mr. Guo Jingbin are the independent non-executive directors.

3